Ewch i’r prif gynnwys

Studies and trials

Mae'r cynnwys hwn ar gael yn Saesneg yn unig.

Filter resultsFilter

1 to 10 of 156 search results

3P Study

Remote delivery of the Group Triple P parenting programme: Optimisation and a Feasibility Randomised Controlled Trial.

ABACus

ABACus (Awareness and beliefs about cancer) is a randomised controlled trial of the health check intervention to improve cancer symptom awareness and help-seeking among people living in socioeconomically deprived communities.

ABC-12

Exploring the microbiome in patients with advanced biliary tract cancer in a first-line study of durvalumab (MEDI4736) in combination with cisplatin/gemcitabine.

ADVANCE

A community-based point of care white cell count device to improve critical care pathways for cancer patients with suspected chemotherapy related neutropenic sepsis: a feasibility study

AML LI-1

LI1 has evaluated 9 novel therapies since the start of the trial in 2011, and continues to do so.

AML15, AML16

In patients given intensive chemotherapy, AML16 for the first time demonstrated the value of measuring response using sophisticated laboratory techniques to identify patients who, although they might be in remission, will relapse early and are therefore candidates for novel treatments or intensification.

AML17

Between 2009 and 2014 AML17 recruited over 3,500 patients aged generally under 60 to what is the largest ever trial in Acute Myeloid Leukaemia run in the UK.

AML18

AML18 is an international trial looking at treatment for acute myeloid leukaemia (AML) and high risk myelodysplastic syndrome (MDS) across approximately 90 centres in the UK and Denmark. It is designed mainly for people over 60 years of age who are fit enough to have intensive chemotherapy.

AML19

AML19 is the current trial for younger adults with acute myeloid leukaemia (AML) or high risk myelodysplastic syndrome (MDS).

ANDREA-LD

Community led ANti-psychotic Drug REduction for Adults with Learning Disabilities: A Randomised Double-blind Placebo Controlled Trial.